Antibe Therapeutics (ATBPF) News Today $0.22 0.00 (0.00%) (As of 12/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period APLIF Appili Therapeutics Inc.August 23, 2024 | seekingalpha.comANTIBE THERAPEUTICS INC (ATBPF) stock forecast and price targetJuly 19, 2024 | finance.yahoo.comAntibe Announces Appointment of ReceiverApril 24, 2024 | finance.yahoo.comAntibe Announces Appointment of ReceiverApril 24, 2024 | businesswire.comAntibe Provides Update on CCAA ProceedingsApril 19, 2024 | businesswire.comAntibe Announces TSX Delisting ReviewApril 16, 2024 | finance.yahoo.comAntibe Announces Granting of Initial Order Under Companies' Creditors Arrangement ActApril 9, 2024 | businesswire.comAntibe to File an Application for an Initial Order Under Companies' Creditors Arrangement ActApril 9, 2024 | businesswire.comAntibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by NuanceApril 1, 2024 | finance.yahoo.comAntibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine MeetingMarch 20, 2024 | businesswire.comAntibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine MeetingMarch 7, 2024 | businesswire.comAntibe Therapeutics Shares Sink After Arbitration Case LostMarch 4, 2024 | marketwatch.comAntibe Therapeutics Stock (OTC:ATBPF), Insider Trading ActivityFebruary 27, 2024 | benzinga.comAntibe Reports Q3 2024 Interim Financial and Operating ResultsFebruary 14, 2024 | finance.yahoo.comAntibe Reports Q3 2024 Interim Financial and Operating ResultsFebruary 14, 2024 | businesswire.comAntibe Therapeutics reports Q2 resultsNovember 13, 2023 | msn.comAntibe Reports PK Results of First Clinical Study of Otenaproxesul’s New FormulationNovember 9, 2023 | finance.yahoo.comIs Antibe Therapeutics (TSE:ATE) In A Good Position To Deliver On Growth Plans?October 20, 2023 | finance.yahoo.comAntibe Initiates First Clinical Study of Otenaproxesul’s New FormulationOctober 18, 2023 | finance.yahoo.comAntibe Announces Results of 2023 Annual MeetingSeptember 8, 2023 | finance.yahoo.comAntibe Reports Q1 2024 Interim Financial and Operating ResultsAugust 14, 2023 | finance.yahoo.comAntibe Reports 2023 Year-End Results and Business HighlightsJune 29, 2023 | finance.yahoo.comClosing Bell: Antibe Therapeutics Inc down on Tuesday (ATE)April 12, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc up on Wednesday (ATE)April 6, 2023 | theglobeandmail.comAntibe Therapeutics Inc. (ATBPF)March 12, 2023 | finance.yahoo.comMaxim Group Reaffirms Their Buy Rating on Antibe Therapeutics (ATBPF)February 16, 2023 | markets.businessinsider.comEchelon Wealth Partners Reaffirms Their Buy Rating on Antibe Therapeutics (ATBPF)February 15, 2023 | markets.businessinsider.comAntibe Therapeutics: Top 25 Undervalued Dividend Stocks on TSX (ATE)February 9, 2023 | theglobeandmail.comAntibe Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (ATE)February 7, 2023 | theglobeandmail.comATBPF: On Track to Initiate Phase 2 Trial for Otenaproxesul in 1H23…November 22, 2022 | finance.yahoo.comAntibe Provides Development Update for OtenaproxesulOctober 12, 2022 | finance.yahoo.comAntibe Announces Results of 2022 Annual MeetingSeptember 9, 2022 | finance.yahoo.comAntibe Academic Collaborator to Present Clinical Data at PAINWeek 2022September 6, 2022 | finance.yahoo.comATE.TO: Phase 2 Post-Operative Pain Program to Initiate in Calendar 4Q22…July 8, 2022 | finance.yahoo.comWill Antibe Therapeutics (TSE:ATE) Spend Its Cash Wisely?July 2, 2022 | finance.yahoo.comAntibe Therapeutics Reports 2022 Year-End Results and Business HighlightsJune 30, 2022 | finance.yahoo.comAntibe Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor ConferenceApril 25, 2022 | nz.finance.yahoo.comAntibe Therapeutics GAAP EPS of -$0.09February 16, 2022 | seekingalpha.comAntibe Therapeutics Reports Q3 2022 Interim Financial and Operating ResultsFebruary 14, 2022 | finance.yahoo.comATBPF Real-Time QuotesJanuary 28, 2022 | nasdaq.comATE.TO: Development Plan in Place for Otenaproxesul in Acute Pain…December 1, 2021 | finance.yahoo.comBRIEF-Antibe Therapeutics Provides Update On Otenaproxesul And Expanded Drug PipelineOctober 14, 2021 | msn.comAntibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug PipelineOctober 14, 2021 | finance.yahoo.comAntibe Therapeutics Announces Results of 2021 Annual MeetingAugust 19, 2021 | finance.yahoo.comAntibe Therapeutics Reports Q1 2022 Interim Financial and Operating ResultsAugust 17, 2021 | businesswire.comATE.TO: Unexpected Liver Enzyme Elevations Leads to Pause in AME Trial…August 4, 2021 | finance.yahoo.com Get Antibe Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATBPF and its competitors with MarketBeat's FREE daily newsletter. Email Address AI breakthrough about to upend industry (Ad)Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing. I urge you to watch it now. ATBPF Media Mentions By Week ATBPF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATBPF News Sentiment▼0.000.60▲Average Medical News Sentiment ATBPF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATBPF Articles This Week▼00▲ATBPF Articles Average Week Get Antibe Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATBPF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LTRN News Today OSTX News Today VRCA News Today BCTX News Today LEXX News Today ATNM News Today RAPT News Today VYNE News Today ANEB News Today TPST News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ATBPF) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antibe Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATBPF Stock Alerts